Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Firefly Neuroscience (AIFF) EBT Margin (2016 - 2025)

Firefly Neuroscience has reported EBT Margin over the past 15 years, most recently at 601.7% for Q4 2025.

  • Quarterly results put EBT Margin at 601.7% for Q4 2025, up 653604.0% from a year ago — trailing twelve months through Dec 2025 was 1740.54% (up 794279.0% YoY), and the annual figure for FY2025 was 1740.54%, up 794279.0%.
  • EBT Margin for Q4 2025 was 601.7% at Firefly Neuroscience, up from 680.15% in the prior quarter.
  • Over the last five years, EBT Margin for AIFF hit a ceiling of 224.63% in Q4 2023 and a floor of 30069.77% in Q1 2025.
  • Median EBT Margin over the past 5 years was 56.61% (2022), compared with a mean of 4047.79%.
  • Peak annual rise in EBT Margin hit 1231682bps in 2025, while the deepest fall reached -2071977bps in 2025.
  • Firefly Neuroscience's EBT Margin stood at 2.22% in 2021, then tumbled by -2256bps to 52.34% in 2022, then surged by 529bps to 224.63% in 2023, then tumbled by -3277bps to 7137.74% in 2024, then surged by 92bps to 601.7% in 2025.
  • The last three reported values for EBT Margin were 601.7% (Q4 2025), 680.15% (Q3 2025), and 611.71% (Q2 2025) per Business Quant data.